7Baggers

Day One Biopharmaceuticals Quarterly Income Statements Chart

Quarterly
 | 
Annual
 
 Operating Profit  
 Net Income  
20210630 20210930 20211231 20220331 20220630 20220930 20221231 20230331 20230630 20230930 20231231 20240331 20240630 20240930 20241231 20250331 20250630 -114.81-93.11-71.42-49.73-28.04-6.3515.3537.04Milllion

Day One Biopharmaceuticals Quarterly Income Statements Table

Quarterly
 | 
Annual
 
Unit: USD2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 
                   
  revenue:                 
  product revenue33,562,000 30,503,000 28,955,000 20,070,000 8,192,000             
  license revenue346,000 258,000 253,000 73,691,000              
  total revenues33,908,000 30,761,000 29,208,000 93,761,000              
  cost and operating expenses:                 
  cost of product and license revenue3,765,000                 
  research and development36,149,000 39,619,000 61,823,000 33,563,000 92,106,000 40,210,000 37,348,000 33,163,000 32,182,000 27,828,000 26,020,000 22,035,000 22,560,000 15,003,000 11,189,000 9,849,000 9,914,000 
  selling, general and administrative28,968,000 29,325,000 29,735,000 28,972,000 30,186,000             
  total cost and operating expenses68,882,000 71,828,000 94,540,000 64,125,000 122,999,000             
  income from operations-34,974,000 -41,067,000 -65,332,000 29,636,000 -114,807,000 -66,767,000 -59,517,000 -51,438,000 -49,254,000 -45,855,000 -42,743,000 -39,699,000 -36,719,000 -27,748,000 -21,975,000 -19,241,000 -15,439,000 
  yoy-69.54% -38.49% 9.77% -157.61% 133.09% 45.60% 39.24% 29.57% 34.14% 65.26% 94.51% 106.33% 137.83%     
  qoq-14.84% -37.14% -320.45% -125.81% 71.95% 12.18% 15.71% 4.43% 7.41% 7.28% 7.67% 8.12% 32.33% 26.27% 14.21% 24.63%  
  operating margin %                 
  non-operating income:                 
  gain from sale of priority review voucher    108,000,000             
  investment income4,671,000 5,094,000 6,052,000 5,322,000 3,962,000 4,365,000 5,024,000 5,291,000 3,406,000 3,466,000        
  other income-19,000 -23,000 40,000 1,197,000 -10,000 -10,000 -18,000 -3,000 -15,000 -4,000 -26,000 9,000  -1,000 14,000 7,000 -27,000 
  total non-operating income4,652,000 5,071,000 6,092,000 6,519,000 111,952,000             
  income before income taxes-30,322,000 -35,996,000 -59,240,000 36,155,000 -2,855,000             
  income tax expense    -1,552,000             
  net income-30,322,000 -35,996,000 -65,714,000 37,037,000 -4,407,000      -40,109,000 -37,795,000 -36,530,000     
  yoy588.04%                 
  qoq-15.76% -45.22% -277.43% -940.41%       6.12% 3.46%      
  net income margin %                 
  net income per share-0.29 -0.35 -0.69 0.38 -0.05 -0.72 -0.64 -0.54 -0.61 -0.59 -0.56 -0.53 -0.6 -0.48 0.36 -0.33 -5.04 
  weighted-average number of common shares used in net income per share - basic103,069,154 102,710,382 93,234,195 96,623,123              
  weighted-average number of common shares used in net income per share - diluted103,069,154 102,710,382 93,234,195 96,937,759              
  cost of product revenue 2,884,000 2,982,000 1,590,000 707,000             
  income tax benefit  -167,500 882,000              
  weighted-average number of common shares used in computing net income per share, basic and diluted    87,121,310 86,679,282 79,773,004 85,952,501 74,964,878 71,972,888 65,466,773 71,008,993 60,760,527 58,382,444 36,960,569 57,514,218 22,661,889 
  operating expenses:                 
  general and administrative     26,557,000 22,169,000 18,275,000 17,072,000 18,027,000 16,723,000 17,664,000 14,159,000 12,745,000 10,786,000 9,392,000 5,525,000 
  total operating expenses     66,767,000 59,517,000 51,438,000 49,254,000 45,855,000 42,743,000 39,699,000 36,719,000 27,748,000 21,975,000 19,241,000 15,439,000 
  net income attributable to common stockholders     -62,412,000 -33,601,500 -46,150,000 -45,863,000 -42,393,000        
  interest income          2,660,000 1,895,000 189,000 2,000    
  net income attributable to redeemable convertible noncontrolling interest                 
  exchange of redeemable noncontrolling interest shares – deemed dividend                -99,994,000 
  net income attributable to common stockholders/members          -40,109,000 -37,795,000 -36,530,000 -27,747,000    
  net income and comprehensive loss             -27,747,000 -21,938,000 -19,240,000 -15,473,000 
  interest expense              -4,750 -6,000 -7,000 
  changes in fair value of derivative tranche liability                 
  net income attributable to redeemable convertible noncontrolling interests                -1,191,000 
  net income attributable to common share members/common stockholders              -37,175,250 -19,240,000 -114,276,000 

We provide you with 20 years income statements for Day One Biopharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Day One Biopharmaceuticals stock. Explore the full financial landscape of Day One Biopharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Day One Biopharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.